FDA Awards Orphan Drug Designation to KT-253 in AML
The FDA has granted an orphan drug designation to the novel, highly potent, and selective MDM2 degrader KT-253 for the treatment of patients with acute myeloid leukemia.
Source: onclive.com
Stay updated with breaking news from Kt 253. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The FDA has granted an orphan drug designation to the novel, highly potent, and selective MDM2 degrader KT-253 for the treatment of patients with acute myeloid leukemia.
NY Burlington VT Zone Forecast for Thursday, September 8, 2022